Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.

Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, Moritz AE, Willette BKA, Fyfe TJ, Jain P, Titus S, Hazelwood LA, Aubé J, Lane JR, Frankowski KJ, Sibley DR.

Mol Pharmacol. 2018 Oct;94(4):1197-1209. doi: 10.1124/mol.118.113175. Epub 2018 Aug 1.

2.

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.

Zou MF, Keck TM, Kumar V, Donthamsetti P, Michino M, Burzynski C, Schweppe C, Bonifazi A, Free RB, Sibley DR, Janowsky A, Shi L, Javitch JA, Newman AH.

J Med Chem. 2016 Apr 14;59(7):2973-88. doi: 10.1021/acs.jmedchem.5b01612. Epub 2016 Apr 1.

3.

Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells.

Yang S, Yang Y, Yu P, Yang J, Jiang X, Villar VA, Sibley DR, Jose PA, Zeng C.

Free Radic Res. 2015 Apr;49(4):397-410. doi: 10.3109/10715762.2015.1006215. Epub 2015 Mar 5.

4.

Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.

Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, Barnaeva E, Ferrer M, Javitch JA, Beuming T, Shi L, Southall NT, Marugan JJ, Sibley DR.

Mol Pharmacol. 2014 Jul;86(1):96-105. doi: 10.1124/mol.113.090563. Epub 2014 Apr 22.

5.

D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.

Chun LS, Free RB, Doyle TB, Huang XP, Rankin ML, Sibley DR.

Mol Pharmacol. 2013 Aug;84(2):190-200. doi: 10.1124/mol.113.085175. Epub 2013 May 16.

6.

Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P.

Int J Neuropsychopharmacol. 2013 Mar;16(2):445-58. doi: 10.1017/S1461145712000661. Epub 2012 Jul 25.

7.

Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice.

Wang X, Luo Y, Escano CS, Yang Z, Asico L, Li H, Jones JE, Armando I, Lu Q, Sibley DR, Eisner GM, Jose PA.

Hypertension. 2010 Jun;55(6):1431-7. doi: 10.1161/HYPERTENSIONAHA.109.148643. Epub 2010 Apr 19.

8.

Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.

Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR.

Synapse. 2009 Jun;63(6):462-75. doi: 10.1002/syn.20626.

9.

The elevated blood pressure of human GRK4gamma A142V transgenic mice is not associated with increased ROS production.

Wang Z, Armando I, Asico LD, Escano C, Wang X, Lu Q, Felder RA, Schnackenberg CG, Sibley DR, Eisner GM, Jose PA.

Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2083-92. Epub 2007 Jan 26.

10.

Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells.

Zeng C, Yang Z, Wang Z, Jones J, Wang X, Altea J, Mangrum AJ, Hopfer U, Sibley DR, Eisner GM, Felder RA, Jose PA.

Hypertension. 2005 Apr;45(4):804-10. Epub 2005 Feb 7.

PMID:
15699451
11.

The hyperthyroid economy.

Sibley DE.

J R Soc Med. 1995 Jun;88(6):305-6. No abstract available.

12.

Transfected D2 short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma x glioma hybrid (NG108-15) cells.

Castellano MA, Liu LX, Monsma FJ Jr, Sibley DR, Kapatos G, Chiodo LA.

Mol Pharmacol. 1993 Sep;44(3):649-56.

PMID:
8371717
13.

Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity.

Barton AC, Kang HC, Rinaudo MS, Monsma FJ Jr, Stewart-Fram RM, Macinko JA Jr, Haugland RP, Ariano MA, Sibley DR.

Brain Res. 1991 May 3;547(2):199-207.

PMID:
1679366
14.

Multiple fluorescent ligands for dopamine receptors. II. Visualization in neural tissues.

Ariano MA, Kang HC, Haugland RP, Sibley DR.

Brain Res. 1991 May 3;547(2):208-22.

PMID:
1884196
15.

Direct visualization and cellular localization of D1 and D2 dopamine receptors in rat forebrain by use of fluorescent ligands.

Ariano MA, Monsma FJ Jr, Barton AC, Kang HC, Haugland RP, Sibley DR.

Proc Natl Acad Sci U S A. 1989 Nov;86(21):8570-4.

16.

Characterization of novel fluorescent ligands with high affinity for D1 and D2 dopaminergic receptors.

Monsma FJ Jr, Barton AC, Kang HC, Brassard DL, Haugland RP, Sibley DR.

J Neurochem. 1989 May;52(5):1641-4.

PMID:
2523470
17.

Dephosphorylation of the beta 2-adrenergic receptor and rhodopsin by latent phosphatase 2.

Yang SD, Fong YL, Benovic JL, Sibley DR, Caron MG, Lefkowitz RJ.

J Biol Chem. 1988 Jun 25;263(18):8856-8.

18.

Subselective measurement of coronary blood flow velocity using a steerable Doppler catheter.

Sibley DH, Millar HD, Hartley CJ, Whitlow PL.

J Am Coll Cardiol. 1986 Dec;8(6):1332-40.

19.

Enhanced adenylate cyclase activity of turkey erythrocytes following treatment with beta-adrenergic receptor antagonists.

Peters JR, Nambi P, Sibley DR, Lefkowitz RJ.

Eur J Pharmacol. 1984 Dec 15;107(1):43-52.

PMID:
6151904
20.

Supplemental Content

Loading ...
Support Center